Search results
Results from the WOW.Com Content Network
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
This page was last edited on 14 February 2021, at 14:06 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
In 2014, Yancopoulos led the launch of the Regeneron Genetics Center, a major initiative in human genetic research that has sequenced exomes from over 1,000,000 people as of February 2020. [23] [24] Forbes magazine states Yancopoulos' financial stake in Regeneron has made him a billionaire. He is the first research and development chief in the ...
On 2 October 2020, Regeneron Pharmaceuticals announced that then-US President Donald Trump had received "a single 8 gram dose of REGN-COV2" after testing positive for SARS-CoV-2. [ 26 ] [ 27 ] The drug was provided by the company in response to a " compassionate use " (temporary authorization for use) request from the president's physicians.
Odronextamab, sold under the brand name Ordspono, is a CD20 x CD3 bispecific monoclonal antibody that is used for the treatment of follicular lymphoma or diffuse large B-cell lymphoma.
Sanofi, in order to get out of its commitment, paid Regeneron $50 million and ceded the rights back to Regeneron. [2] The drug was a blockbuster generating $838 million in its first full year and sales increased 55% to $1.3 billion in 2013 [3] making Schleifer a billionaire. [2] In 2014 Eylea grossed $1.735 billion. [4]
Garetosmab is a fully human, experimental monoclonal antibody against activin-A.It has been tried in patients with fibrodysplasia ossificans progressiva and the manufacturer, Regeneron, also plans to test it in patients with obesity as an add-on to existing weight loss drugs such as GLP-1 agonists, in order to help patients maintain muscle mass during weight loss.
This drug was developed by Regeneron Pharmaceuticals, Inc. [2] References This page was last edited on 15 June ...